The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)

NCT05951751 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2800

Last updated 2024-06-20

No results posted yet for this study

Summary

The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia.

The TRI-MOM program has two components:

1. an "intervention" component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT.
2. an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.

Conditions

  • Hiv
  • Syphilis
  • HBV

Interventions

OTHER

TRI-MOM intervention

The TRI-MOM strategy includes 4 main activities: 1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services) 2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests 3. Assessment and treatment of women positive for any of the 3 targeted infections 4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections

Sponsors & Collaborators

  • Centre Muraz

    collaborator OTHER
  • Medical Research Council

    collaborator OTHER_GOV
  • Institut Pasteur

    collaborator INDUSTRY
  • REVS PLUS Burkina Faso

    collaborator UNKNOWN
  • Young Gambian Mums Fund

    collaborator UNKNOWN
  • National AIDS Control Program Gambia

    collaborator UNKNOWN
  • Institut de Recherche pour le Developpement

    lead OTHER_GOV

Principal Investigators

  • Sylvie Boyer, PhD · UMR 1252 SESSTIM

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-18
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Burkina Faso
  • The Gambia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05951751 on ClinicalTrials.gov